AstraZeneca entered exclusive licensing agreement with CSPC for YS2302018, an early-stage oral small molecule Lp(a) disruptor with potential combination use with AZ's AZD0780 PCSK9 inhibitor. CSPC receives $100M upfront plus up to $1.92B in development and commercial milestones and tiered royalties. Top-25 pharma buyer.